Story perspectives

Funding Boost for S.V.F. Advances ADHD Treatment Research

1/25/2026

Summary

Story summary

S.V.F. received financial support from multiple companies, including Aardvark and Johnson & Johnson.
S.V.F. holds a U.S. patent for sodium-hydrogen exchange inhibitors in Attention-Deficit/Hyperactivity Disorder (ADHD) treatment.
S.V.F. earns royalties from Guilford Press, Oxford University Press, and Elsevier.
S.V.F. directs the ADHD Evidence Project.
J.H.N. serves as a consultant for AGB Pharma and Otsuka and has received research funding from Cingulate and Supernus, plus honoraria for lectures from Apsen.

1 of 1

Story summary

S.V.F. received financial support from multiple companies, including Aardvark and Johnson & Johnson.
S.V.F. holds a U.S. patent for sodium-hydrogen exchange inhibitors in Attention-Deficit/Hyperactivity Disorder (ADHD) treatment.
S.V.F. earns royalties from Guilford Press, Oxford University Press, and Elsevier.
S.V.F. directs the ADHD Evidence Project.
J.H.N. serves as a consultant for AGB Pharma and Otsuka and has received research funding from Cingulate and Supernus, plus honoraria for lectures from Apsen.